검색
Regenxbio Inc
RGNX관심 목록에 추가
13.280USD
+0.190+1.45%
종가 07/02, 13:00（ET）시세는 15분 지연됩니다
686.54M시가총액
손실P/E TTM
자세한 내용은 Regenxbio Inc 회사
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. It is focused on its internal development pipeline in three areas: retinal, neuromuscular, and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202, RGX-121, and RGX-111. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Regenxbio Inc 정보
종목 코드 RGNX
회사 이름Regenxbio Inc
상장일Sep 17, 2015
CEOSimpson (Curran M)
직원 수353
유형Ordinary Share
회계 연도 종료Sep 17
주소9804 Medical Center Drive
도시ROCKVILLE
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호20850
전화12405528181
웹사이트https://regenxbio.com/
종목 코드 RGNX
상장일Sep 17, 2015
CEOSimpson (Curran M)
Regenxbio Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+57.74%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+78.61%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-123.06%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
45.81K
-165.45%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
31.87K
+30.77%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
28.86K
+33.98%
Mr. George V. Migausky
Mr. George V. Migausky
Independent Director
Independent Director
28.86K
+33.98%
Mr. Kenneth T. (Ken) Mills
Mr. Kenneth T. (Ken) Mills
Chairman of the Board
Chairman of the Board
--
--
Dr. A. N. (Jerry) Karabelas, Ph.D.
Dr. A. N. (Jerry) Karabelas, Ph.D.
Independent Director
Independent Director
--
--
Mr. Allan M. Fox, J.D.
Mr. Allan M. Fox, J.D.
Director
Director
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Mitchell Chan
Mr. Mitchell Chan
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
127.72K
+57.74%
Mr. Craig Malzahn
Mr. Craig Malzahn
Executive Vice President - Product Development, Chief Technology Officer
Executive Vice President - Product Development, Chief Technology Officer
82.19K
+78.61%
Dr. Olivier Danos, Ph.D.
Dr. Olivier Danos, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
58.37K
-123.06%
Mr. Curran M. Simpson
Mr. Curran M. Simpson
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
45.81K
-165.45%
Ms. Jennifer L. Zachary
Ms. Jennifer L. Zachary
Independent Director
Independent Director
31.87K
+30.77%
Mr. Daniel Tasse
Mr. Daniel Tasse
Lead Independent Director
Lead Independent Director
28.86K
+33.98%
자주 묻는 질문
Regenxbio Inc의 상위 5대 주주는 누구인가요?
Regenxbio Inc의 상위 5대 주주는 다음과 같습니다: Mr. Mitchell Chan
Regenxbio Inc(RGNX)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Regenxbio Inc의 주식을 보유한 기관은 총 410곳이며, 이들이 보유한 주식의 총 가치는 약 45.28M로 전체 발행 주식의 87.72%를 차지합니다. 이는 2025Q4 대비 -3475301.00 증가한 수치입니다.